Effect of an vitamin D deficiency on depressive symptoms in child and adolescent psychiatric patients - a randomized controlled trial: study protocol.
BMC Psychiatry. 2018 Mar 1;18(1):57. doi: 10.1186/s12888-018-1637-7.
Föcker M1, Antel J2, Grasemann C3, Führer D4, Timmesfeld N5, Öztürk D2, Peters T2, Hinney A2, Hebebrand J2, Libuda L2.
- Both the main and the control arm of the trial will get 2640 IU(?) of vitamin D daily (q.d.)
- but for only 28 days
- Very unlikely that this small amount of vitamin D for such a short time will actually help
That small of a dose might help in trials lasting 100 days, but not 28 days
- But, it is an interesting way of getting around the moral problem of not giving Vitamin D to all trial participants
- Depression category listing has
210 items along with related searches
- Anti-depression medication about as good as big increase in vitamin D – meta-analysis of flawless data April 2014
- Depression – is it reduced by Vitamin D and or Omega-3 – RCT 2019
Depression is a significant health and economic burden worldwide affecting not only adults but also children and adolescents. Current treatment options for this group are scarce and show moderate effect sizes. There is emerging evidence that dietary patterns and specific nutritional components might play a role in the risk for developing depression. This study protocol focusses on the role of vitamin D which is for long known to be relevant for calcium and phosphorous homeostasis and bone health but might also impact on mental health. However, the assessment of the vitamin D status of depressed juvenile patients, or supplementation of vitamin D is currently not part of routine treatment. Controlled intervention studies are indispensable to prove whether a vitamin D deficiency ameliorates depressive symptoms.
This double blinded, randomized controlled trial will enroll 200 inpatients from a child and adolescent psychiatric department with a vitamin D deficiency defined by a 25(OH)-vitamin D-level < 30 nmol/l (12 ng/ml) and a Beck Depressions Inventory (BDI-II) score > 13 (indicating at least: mild depression). Upon referral, all patients will be screened, checked for inclusion criteria, and those eligible will be randomized after written consent into a supplementation or placebo group. Both study-arms will receive treatment-as-usual for their psychiatric disorder according to established clinical guidelines. The participants of the vitamin D supplementation group will receive 2640 I.E. vitamin D3 q.d. for 28 days in accordance with best practice in pediatric endocrinology. We hypothesize that delaying supplementation of vitamin D in the placebo arm will affect the treatment success of the depressive symptomatology in comparison to the vitamin D supplementation group. Patients will be enrolled for a period of 28 days based on the mean length of hospitalization of juveniles with depression.
Randomized controlled trials in children and adolescents with depression are needed to elucidate the role of a vitamin D deficiency for mental disorders and to investigate the relevance of a routine assessment and supplementation of vitamin D deficits.
TRIAL REGISTRATION: DRKS00009758, 16/06/2016 (retrospectively registered).